Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

NCT07245771 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity &Amp; Overweight

Interventions

DRUG: RN3161
DRUG: Placebo Control
DRUG: Tirzepatide

Sponsor

Ikaria Bioscience Pty Ltd

Collaborators

[object Object]